Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stock Watch: Hedging The Effects Of Omicron

Do Pandemic-Related Pharmaceutical Stocks Offset Others That React Badly To Pandemic Pressures?

Executive Summary

As well as hedging investors’ portfolios against the effects of pandemic waves, the stock prices of Pfizer and Merck & Co seem to be negatively correlated to each other, just as their pandemic-related revenues are to their traditional drug sales.

You may also be interested in...



Divided US FDA AdComm Backs Molnupiravir Authorization But Wants More Studies

In 13-10 vote, panel finds reduction in COVID-19 hospitalizations and deaths outweighs risks. Four members say FDA should reconsider authorization if a more effective and safer therapy comes along. They concur molnupiravir should not be recommended for use in pregnancy but available to those who want it.

MSD's COVID-19 Pill Molnupiravir Gains First Approval In UK

The UK becomes the first country to grant a marketing authorization for the oral treatment which could help cut hospitalizations and deaths by half.

Stock Watch: Alnylam’s Date With The Competition

When a loss-making rare disease biotech company’s product takes on Pfizer in the same indication but without the benefit of superior data, pharmaceutical marketing lessons will be learnt.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145532

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel